46. Malignant rheumatoid arthritis Clinical trials / Disease details
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04349046 (ClinicalTrials.gov) | January 1, 2021 | 14/4/2020 | Exception Cementless Hip Stem | Exception Cementless Femoral Stem in Total Hip Arthroplasty. A Multicenter, Retrospective and Prospective, Non-controlled Post Market Clinical Follow-up Study (Implants and Instrumentation) | Osteoarthritis, Hip;Rheumatoid Arthritis;Inflammatory Arthritis;Congenital Hip Dysplasia;Avascular Necrosis of Hip;Femoral Neck Fractures | Device: Total hip arthoplasty (THA) | Zimmer Biomet | NULL | Recruiting | 18 Years | 100 Years | All | 332 | Belgium;France |